Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K current report with the SEC on June 12, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders elected Richard A. Miller and Linda S. Grais as Class I directors through the 2029 annual meeting.
Corvus Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Shareholders elected Richard A. Miller and Linda S. Grais as Class I directors through the 2029 annual meeting
- Director support: Miller 58,275,179 votes; Grais 53,185,380 votes
- PwC selection ratified for fiscal year ending December 31, 2026, with 72,864,335 votes in favor
- Executive compensation approved on a non-binding basis, with 58,936,532 votes in favor
- 73,021,854 of 84,090,424 outstanding shares voted, representing approximately 87% participation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corvus Pharmaceuticals, Inc. 8-K filings
Get the next CRVS 8-K as it lands
Follow CRVS for push alerts, or ask the research agent what this filing means.